Table 2.
Clinical characteristics of PD patients
| Author | Year | Sample size | Age (years) | Sex (%F) | Disease duration (years) | UPDRS III | HY | Cognition |
|---|---|---|---|---|---|---|---|---|
| Ma et al. | 2022 | 51 | 65.7 | 35.3 | 8.0 (4.4) | 33.6 | 2.4 | 26.1 (3.4) |
| Lindholm et al. | 2021 | 58 | 68 | 55 | 4.0 (3.9) | 12 | 2 | 28 (26–29) |
| Van Schooten et al. | 2021 | 305 | 68.2 | 53.1 | – | – | – | 29.0 (1.6) |
| Lindholm et al. | 2020 | 73 | 65 | 55.1 | 3.2 (3.7) | 10 | 2 | 28 (27–29) |
| Venhovens et al. | 2020 | 30 | 70 | 13.3 | 5 | – | 2.5 | – |
| Geerse et al. | 2019 | 30 | 63.1 | 40 | – | 36.9 | 2.3 | – |
| Romagnolo et al. | 2019 | 50 | 65.1 | 32 | 8.23 (5.13) | 21.2 | - | 25.7 (4.4) * |
| Beretta et al. | 2018 | 28 | 72.5 | 35.7 | – | 23.92 | 1.92 | 28.5 (1.7) |
| Almeida et al. | 2016 | 229 | 70.7 | 45.8 | No falls: 4.8 (3.6) | 32.55 | 2.75 | – |
| Falls: 8.6 (5.4) | ||||||||
| Cole et al. | 2016 | 81 | 68.1 | 36.4 | 6.1 (0.5) | 34.7 | 1.9 | – |
| Custodio et al. | 2016 | 59 | 67 | 40.7 | 6 | 24 | – | – |
| Gazibara et al. | 2016 | 120 | 60 | 66.6 | 4 | – | 2.25 | – |
| Heinzel et al. | 2016 | 40 | 64.3 | 62.4 | No falls: 3.5 (2.6) | 32.6 | 2.45 | No falls: 26.7 (2.4) |
| Falls: 5.5 (3.1) | Falls: 26.9 (2.2) | |||||||
| Lord et al. | 2016 | 121 | 68.4 | 61.4 | 0–0.2 | 24.1 | 2.8 | No falls: 25.9 (3.0) |
| Falls: 25.0 (3.4) | ||||||||
| Sakushima et al. | 2016 | 97 | 71.4 | 59.2 | No falls: 6.1 | 16.2 | 2.65 | No falls: 26.4 (3.0) |
| Falls: 9.4 | Falls: 26.4 (2.7) | |||||||
| Schlenstedt et al. | 2016 | 85 | 67.1 | 33.3 | No falls: 6.9 (5.2) | 42.1 | 2.65 | – |
| Falls: 9.3 (6.5) | ||||||||
| Almeida et al. | 2015 | 130 | 70.3 | 41.8 | 4.9 (3.6) | 26.8 | 2.5 | 29.2 (1.2) |
| Duncan et al. | 2015 | 171 | 67.0 | 44 | No falls: 4.8 (3.8) | 32.48 | – | – |
| Falls: 6.6 (4.2) | ||||||||
| Gazibara et al. | 2015 | 120 | 61.4 | – | – | – | 2 | – |
| Hoskovcová et al. | 2015 | 45 | 67.2 | 24.4 | 10.2 (3.4) | 22.6 | 2.6 | 24.2 (3.3) * |
| Kataoka and Ueno | 2015 | 85 | 71.3 | – | 4.8 | 41.1 | 2.8 | 26.8 (3.2) |
| Hiort et al. | 2014 | 124 | 70.4 | 49 | 6.9 (4.3) | 20.3 | – | 27.3 (3.7) |
| Kataoka et al. | 2014 | 26 | 65.3 | 46.2 | No falls: 72.6 (69.0)† | 18.65 | – | No falls: 28.4 (1.5) |
| Falls: 88.0 (61.2)† | Falls: 26.1 (3.3) | |||||||
| Mak et al. | 2014 | 144 | 63.4 | 38.5 | No falls: 7.1 (4.8) | 29.9 | 2.55 | – |
| Falls: 9.5 (7.8) | ||||||||
| Duncan et al. | 2013 | 80 | 68.2 | 41.3 | – | 41.3 | 2.5 | – |
| Kim et al. | 2013 | 119 | 65.5 | 56.5 | No falls: 1.1 (0.5) | 19.75 | – | No falls: 26.6 (2.6) |
| Falls: 1.3 (0.6) | Falls: 26.6 (2.2) | |||||||
| Mak et al. | 2013 | 110 | 62.9 | 22 | No falls: 6.7 (4.4) | 26.2 | 2.75 | No falls: 28.0 (2.3) |
| Falls: 9.0 (6.2) | Falls: 27.8 (2.7) | |||||||
| Paul et al. | 2013 | 205 | 67.8 | 41 | No falls: 5.4 (4.0) | 24.65 | – | No falls: 29.2 (1.0) |
| Falls: 8.7 (6.5) | Falls: 28.8 (1.3) | |||||||
| Camicioli et al. | 2010 | 52 | 71.5 | 42.3 | – | 17.7 | 2.25 | 28.0 (1.75) |
| Allcock et al. | 2009 | 176 | 71.2 | 37.2 | 7.2 | 19 | – | 25.1 (3.5) |
| Latt et al. | 2009 | 113 | 66 | 41.6 | – | – | – | No falls: 12.9%a |
| Falls: 33.3%a | ||||||||
| Mak et al. | 2009 | 70 | 63.4 | 49.8 | No falls: 7.2 (4.2) | 25.4 | 2.9 | – |
| Falls: 7.2 (4.2) | ||||||||
| Wood et al. | 2002 | 109 | 74.7 | 52.3 | 3 (1–31) | 32.5 | 2 | No falls: 29 (19–30) |
| Falls: 27 (0–30) | ||||||||
| Gray et al. | 2000 | 118 | – | 38 | – | 50.5 | 2.55 | – |
Data is provided as mean (SD) or median (Q1 - Q3). F female, HY Hoehn & Yahr scale, PD, Parkinson’s disease
† Disease duration is represented in months
* Cognition was tested with MoCA instead of MMSE
a Proportion of PD patients with MMSE score ≤ 27/30